Company*
(Country; Symbol)		 Company
(Country; Symbol)		 Type/Product Area Terms/Details (Date)
I. MODIFIED AGREEMENTS
Archemix Corp.* NascaCell Technologies AG (Germany; BE:N7C) Expanded alliance on the use and development of aptamers, a new generation of biomolecules NascaCell receives nonexclusive rights to uses of aptamers for target validation, mode-of-action studies, drug discovery and aptamer structure-based drug design (2/12)
BioMarin Pharmaceutical Inc. (BMRN) Genzyme Corp. (GENZ) Redone joint venture regarding Aldurazyme (laronidase) for mucopolysaccharidosis I The revised structure calls for BioMarin to receive a tiered royalty ranging from about 39.5% to 50% of worldwide net sales, instead of the two firms sharing all costs and profits equally through the 50/50 joint venture (1/4)
Callisto Pharmaceuticals Inc. (AMEX:KAL) Genzyme Corp. (GENZ) Restructured license agreement for Atiprimod to treat advanced carcinoid cancer The restructured agreement eliminates all milestone payments and reduces royalties owed to Genzyme to single digits; in return, Callisto is paying an up-front fee this year (1/7)
GTC Biotherapeutics Inc. (GTCB) LFB Biotechnologies* (subsidiary of LFB SA; France) Expanded collaboration to develop recombinant plasma proteins and monoclonal antibodies using GTC's transgenic production platform Both companies will share costs and profits, with LFB funding a $500,000 license fee payment due to ProGenetics LLC in the second quarter of 2008; GTC will get North American rights while LFB receives European and Japanese rights (1/10)
ExonHit Therapeutics SA (France; PK:EXHTF) bioMerieux SA(France; PARIS:BIM) Amended cancer diagnostics partnership The new agreement gives ExonHit commercial rights to diagnostic kit development through the alliance and allows bioMerieux greater flexibility to start new research and development projects in that field (1/9)
MethylGene Inc. (Canada; TSX:MYG) EnVivo Pharmaceuticals* MethylGene exercised its right to opt out of further funding in its collaboration with EnVivo EnVivo will continue to research and develop histone deacetylase inhibitors for neurodegenerative disorders such as Huntington's, Alzheimer's and Parkinson's disease under license from MethylGene; MethylGene will receive royalties on net sales on any approved product, as well as a share of any sublicense income from future partnerships (2/6)
Novozymes (UK; LSE:NVZ) Upperton Ltd.* (UK) Extended collaboration for commercial exploitation of the jointly owned rP-nano technology Upperton will use rP-nano to generate nanoparticles from recombinant proteins expressed in Novozymes' yeast-based expression system (2/20)
Nutra Pharma Corp. (OTC BB: NPHC) NanoLogix Inc. (PK:NNLX) Expanded licensing agreement to include intellectual property for the use of testing the environment for non-tuberculosis mycobacterium Further terms were not disclosed (12/27)
II. TERMINATED AGREEMENTS
Altus Pharmaceuticals Inc. (ALTU) Genentech Inc. (NYSE:DNA) Terminated agreement in which Genentech gave back the North American rights to the once-weekly, subcutaneous human growth hormone ALTU-238 The decision was made due to business issues, not scientific development issues (12/20)
Osiris Therapeutics Inc. (OSIR) Boston Scientific Corp. (NYSE:BSX) Terminated agreement for Prochymal for cardiovascular indications Osiris regained all rights to its stem cell technology, in exchange for relieving Boston Scientific of a $50M loan obligation and $45M in development payments; Osiris agreed to repay a $5M debt, plus accrued interest in four quarterly installments (1/7)
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. AMEX = American Stock Exchange; BE = Berlin Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSX = Toronto Stock Exchange.